wilate

Press Release » Octapharma Receives Orphan Drug Exclusivity Approval for wilate (R) - A Replacement Therapy Developed Specifically for von Willebrand Disease Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

Medindia Health News 2010

The wilate® manufacturing process provides two independent and effective virus inactivation procedures, namely S/D treatment in bulk and TDH treatment of the lyophilized product in final container.

Medindia Health News 2010

The FDA's approval and granting of orphan drug exclusivity of wilate® marks the entrance of Octapharma USA into the U.S. blood coagulation market, with product availability scheduled for early 2010.

THE MEDICAL NEWS 2010

D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack Obama reportedly supportive of House bid to include national exchanges in health bill First genetic map of malaria drug plant could increase crop yields, study says New findings may yield novel therapies for chronic neurodegenerative diseases FD. grants orphan drug exclusivity approval for Octapharma AG's wilate D.spute erupts between Reid and Lieberman around 'double-cross' quote

THE MEDICAL NEWS 2010

D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack Obama reportedly supportive of House bid to include national exchanges in health bill First genetic map of malaria drug plant could increase crop yields, study says New findings may yield novel therapies for chronic neurodegenerative diseases FD. grants orphan drug exclusivity approval for Octapharma AG's wilate D.spute erupts between Reid and Lieberman around 'double-cross' quote

THE MEDICAL NEWS 2010

There is a possibility that wilate® can cause hypersensitivity or allergic reactions.

Medindia Health News 2010

The FDA's approval and granting of orphan drug exclusivity of wilate® marks the entrance of Octapharma USA into the U.S. blood coagulation market, with product availability scheduled for early 2010.

Medindia Health News 2010

The most common related Adverse Reactions observed during the wilate® clinical studies include: urticaria and dizziness.

Medindia Health News 2010

In addition, the ion-exchange chromatography step utilized during wilate® manufacturing contributes to the viral safety.

Medindia Health News 2010

"The FDA orphan drug exclusivity approval for wilate® is an important aspect in Octapharma ` s development of this drug," said Kim Bjornstrup, Vice Chairman Octapharma Group.

Medindia Health News 2010